BDRX שווי כולל של נכסי החברה Biodexa Pharma

Biodexa Pharmaceuticals (BDRX) is developing biopharmaceuticals for rare brain tumors, leveraging eRapa data and orphan drug status. The proprietary Tolervin microspheres create a powerful defensive barrier despite strict FDA oversight. The confirmed price history on the total assets chart is 18.60, while business scalability remains zero as all resources are consumed by laboratory research expenses.

The dynamics of Biodexa Pharmaceuticals (BDRX) total resource volume, reverse-calculated via return on assets (ROA), allow for an assessment of the company's material base stability amid geopolitical fragmentation limiting access to international clinical trials; an analysis of the organization's asset levels reveals the degree of degradation or recovery of production capacity, which is critical for drug certification during the disruption of global logistics chains.